

REPLIGEN CORP  
Form SC 13G/A  
September 23, 2003

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**SCHEDULE 13G**  
**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO 13d-2(b)  
(Amendment No. 5)\***

**Repligen Corporation**

---

(Name of Issuer)

**Common Stock**

---

(Title of Class of Securities)

**759916 10 9**

---

(CUSIP Number)

**September 17, 2003**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No. 759916 10 9

**13G**

---

Page 2 of 11 Pages

---

---

**1** NAME OF REPORTING PERSON:  
**Biotechnology Value Fund, L.P.**  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

---

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a)  x  
(b)  o

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES	5	SOLE VOTING POWER	0
BENEFICIALLY OWNED BY EACH REPORTING PERSON	6	SHARED VOTING POWER	292,263
WITH:	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	292,263

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
292,263

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*  o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
0.98%

12 TYPE OF REPORTING PERSON\*  
PN

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

CUSIP No. 759916 10 9

13G

Page 3 of 11 Pages

1 NAME OF REPORTING PERSON:  
**Biotechnology Value Fund II, L.P.**  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a)  x  
(b)  o

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES	7	SOLE VOTING POWER	0
BENEFICIALLY OWNED BY EACH REPORTING PERSON	6	SHARED VOTING POWER	215,179
WITH:	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	215,179

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
215,179

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
0.72%

12 TYPE OF REPORTING PERSON\*  
PN

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

CUSIP No. 759916 10 9

**13G**

Page 4 of 11 Pages

1 NAME OF REPORTING PERSON:  
**BVF Investments, L.L.C.**  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  (a) x  
 (b) o

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

---

NUMBER OF SHARES	5	SOLE VOTING POWER	0
BENEFICIALLY OWNED BY EACH REPORTING PERSON	6	SHARED VOTING POWER	318,221
WITH:	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	318,221

---

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

318,221

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.07%

12 TYPE OF REPORTING PERSON\*

OO

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

---

CUSIP No. 759916 10 9

**13G**

Page 5 of 11 Pages

---

1 NAME OF REPORTING PERSON:

**Investment 10, LLC**

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) x

(b) o

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

Edgar Filing: REPLIGEN CORP - Form SC 13G/A

NUMBER OF SHARES	5	SOLE VOTING POWER	0
BENEFICIALLY OWNED BY EACH REPORTING PERSON	6	SHARED VOTING POWER	6,300
WITH:	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	6,300

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,300

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.02%

12 TYPE OF REPORTING PERSON\*

OO

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

CUSIP No. 759916 10 9

**13G**

Page 6 of 11 Pages

1 NAME OF REPORTING PERSON:  
**BVF Partners L.P.**  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  (a)  (b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES	5	SOLE VOTING POWER	0
BENEFICIALLY	6	SHARED VOTING POWER	

OWNED BY		<b>831,963</b>
EACH REPORTING PERSON	7	SOLE DISPOSITIVE POWER <b>0</b>
WITH:	8	SHARED DISPOSITIVE POWER <b>831,963</b>

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
**831,963**

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
**2.79%**

12 TYPE OF REPORTING PERSON\*  
**PN**

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

CUSIP No. 759916 10 9

**13G**

Page 7 of 11 Pages

1 NAME OF REPORTING PERSON:  
**BVF Inc.**  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  (a) x  
 (b) o

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
**Delaware**

NUMBER OF SHARES	5	SOLE VOTING POWER <b>0</b>
BENEFICIALLY OWNED	6	SHARED VOTING POWER <b>831,963</b>

BY		
EACH REPORTING PERSON	7	SOLE DISPOSITIVE POWER 0
WITH:	8	SHARED DISPOSITIVE POWER 831,963

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
831,963

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\* 0

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
2.79%

12 TYPE OF REPORTING PERSON\*  
CO

**\*SEE INSTRUCTIONS BEFORE FILLING OUT!**

CUSIP No. 759916 10 9

13G

Page 8 of 11 Pages

**ITEM 1(a). NAME OF ISSUER:**

Repligen Corporation ("Repligen")

**ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:**

41 Seyton Street  
Building 1, Suite 100  
Waltham, Massachusetts 02453

**ITEM 2(a). NAME OF PERSON FILING:**

This Amendment to Schedule 13G is being filed on behalf of the following persons\* (the "Reporting Persons"):

- (i) Biotechnology Value Fund, L.P. ('BVF')
- (ii) Biotechnology Value Fund II, L.P. ('BVF2')
- (iii) BVF Investments, L.L.C. ('Investments')
- (iv) Investment 10, L.L.C. ('Investment 10')

(v) BVF Partners L.P. ('Partners')

(vi) BVF Inc. ('BVF Inc.')

\* Attached as Exhibit 1 is a copy of an agreement among the Reporting Persons that this Amendment to Schedule 13G is being filed on behalf of each of them.

**ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:**

The principal business office of the Reporting Persons comprising the group filing this Amendment to Schedule 13G is located at 227 West Monroe Street, Suite 4800, Chicago, Illinois, 60606.

**ITEM 2(c). CITIZENSHIP:**

BVF:	a Delaware limited partnership
BVF2:	a Delaware limited partnership
Investments:	a Delaware limited liability company
Investment 10:	an Illinois limited liability company
Partners:	a Delaware limited partnership
BVF Inc.:	a Delaware corporation

**ITEM 2(d). TITLE OF CLASS OF SECURITIES:**

This Amendment to Schedule 13G is being filed with respect to the common stock, par value \$.01 per share (the 'Common Stock'), of Repligen. The Reporting Persons' percentage ownership of Common Stock is based on 29,859,173 shares of Common Stock being outstanding.

**ITEM 2(e). CUSIP Number:**

759916 10 9

---

CUSIP No. 759916 10 9

13G

Page 9 of 11 Pages

---

**ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS: One of the following**

Not applicable as this Amendment to Schedule 13G is filed pursuant to Rule 13d-1(c).

**ITEM 4. OWNERSHIP:**

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment to Schedule 13G is hereby incorporated by reference.

**ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:**

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. x

**ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:**

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of the Common Stock and to vote and exercise dispositive power over those shares of Common Stock. Partners and BVF Inc. share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Investments and those owned by Investment 10, on whose behalf Partners acts as investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of Common Stock owned by such parties.



**ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:**

Not applicable.

**ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:**

Not applicable.

**ITEM 9. NOTICE OF DISSOLUTION OF GROUP:**

Not applicable.

---

CUSIP No. 759916 10 9

13G

Page 9 of 11 Pages

---

**ITEM 10. CERTIFICATION**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 23, 2003

**BIOTECHNOLOGY VALUE FUND, L.P.**

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

---

Mark N. Lampert  
President

**BIOTECHNOLOGY VALUE FUND II, L.P.**

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

---

Mark N. Lampert  
President

**BVF INVESTMENTS, L.L.C.**

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

---

Mark N. Lampert  
President

**INVESTMENT 10, L.L.C.**

By: BVF Partners L.P., its attorney-in-fact

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

\_\_\_\_\_  
Mark N. Lampert  
President

**BVF PARTNERS L.P.**

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

\_\_\_\_\_  
Mark N. Lampert  
President

**BVF INC.**

By: /s/ MARK N. LAMPERT

\_\_\_\_\_  
Mark N. Lampert  
President

---